"Lipid Nanoparticle delivery of siRNA to unravel chronic pain"
In this webinar, Dr. Marc-Andre Dansereau from the Université de Sherbrooke will describe how RNAi was used to better understand how the CCL2 chemokine and its receptor, CCR2, contribute to the development of chronic pain. Altough CCR2 has been identified as an interesting target for the development of a new class of analgesic drug, its regulation in the context of chronic pain is still widely unknown.
Injecting Dicer-substrate siRNA against CCL2 or CCR2 encapsulated in lipid nanoparticles (LNP) into the intrathecal space after the induction of chronic inflammatory pain in rats revealed a biphasic contribution of this chemokine system, as well as a differential role of dorsal root ganglia-derived CCL2 and CCR2.
In this webinar, Professor Pieter Cullis from the University of British Columbia unpacked the application of microfluidics for the preparation of "limit-size" lipid nanoparticle systems including liposomes, nanoemulsions and RNA-lipid nanoparticles (RNA-LNP). "Limit size" is defined as the smallest energetically and thermodynamically stable structure possible based on the packing constraints of the component molecules. Smaller lipid nanoparticle systems can impact the activity of their payloads by altering biodistribution for example by penetrating deeper into solid tumors. Also, smaller systems are amenable to alternative administration routes such as subcutaneous injection.
If you missed the webinar on February 18th, you can now view it below!
Extracellular vesicles (EVs) have emerged as important mediators of intercellular communication and are involved in the transmission of biological signals between cells to regulate a broad range of biological processes. Interest in them is growing exponentially as their role in physiology, pathology and their therapeutic potential is recognized.
Webinars Precision Nanosystems & IZON Science
"Lipid Nanoparticle delivery of siRNA to unravel chronic pain"
In this webinar, Dr. Marc-Andre Dansereau from the Université de Sherbrooke will describe how RNAi was used to better understand how the CCL2 chemokine and its receptor, CCR2, contribute to the development of chronic pain. Altough CCR2 has been identified as an interesting target for the development of a new class of analgesic drug, its regulation in the context of chronic pain is still widely unknown.
Injecting Dicer-substrate siRNA against CCL2 or CCR2 encapsulated in lipid nanoparticles (LNP) into the intrathecal space after the induction of chronic inflammatory pain in rats revealed a biphasic contribution of this chemokine system, as well as a differential role of dorsal root ganglia-derived CCL2 and CCR2.
Wed, Mar 16, 2016 6:30 PM - 7:30 PM CET
Register HERE
In this webinar, Professor Pieter Cullis from the University of British Columbia unpacked the application of microfluidics for the preparation of "limit-size" lipid nanoparticle systems including liposomes, nanoemulsions and RNA-lipid nanoparticles (RNA-LNP). "Limit size" is defined as the smallest energetically and thermodynamically stable structure possible based on the packing constraints of the component molecules. Smaller lipid nanoparticle systems can impact the activity of their payloads by altering biodistribution for example by penetrating deeper into solid tumors. Also, smaller systems are amenable to alternative administration routes such as subcutaneous injection.
If you missed the webinar on February 18th, you can now view it below!
View the webinar
Webinar Date: March 10, 2016
Time: 8:00 AM PST/11:00 AM EST/15:00 GMT
REGISTER NOW
Extracellular vesicles (EVs) have emerged as important mediators of intercellular communication and are involved in the transmission of biological signals between cells to regulate a broad range of biological processes. Interest in them is growing exponentially as their role in physiology, pathology and their therapeutic potential is recognized.
Related products
qNano Gold